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11 Abstract
12 Fe-deficiency anaemia is a worldwide health problem. We studied the influence of consuming an Fe-fortified fruit juice on Fe status in
13 menstruating women. A randomised, double-blind, placebo-controlled study of 16 weeks of duration was performed. Subjects were ran-Q1
14 domised into two groups: such as P group (n 58) or F group (n 64), consumed, as a supplement to their usual diet, 500 ml/d of a placebo
15 fruit juice or an Fe-fortified fruit juice, respectively. The Fe-fortified fruit juice, containing microencapsulated iron pyrophosphate, provided
16 18 mg of Fe (100 % of the RDA). At baseline and monthly, dietary intake, body weight and Fe parameters were determined: total erythro-
17 cytes, haematocrit, mean corpuscular volume (MCV), red blood cell distribution width (RDW), Hb, serum Fe, serum ferritin, serum trans-
18 ferrin, transferrin saturation, soluble transferrin receptor (sTfR-2) and zinc protoporphyrin (ZnPP). The fruit juice consumption involved
19 increased intake of carbohydrates and vitamin C, and increased BMI within normal limits. Ferritin was higher in the F group after
20 week 4 (P,0·05) and became 80 % higher than in the P group after week 16 (P,0·001), and transferrin decreased in the F group compared
21 with the P group after week 4 (P,0·001). RDW was higher at weeks 4 and 8 in the F group compared with the P group (P,0·05). Trans-
22 ferrin saturation increased after week 8, and haematocrit, MCV and Hb increased after week 12, in the F group compared with the P group.
23 Serum Fe did not change. sTfR and ZnPP decreased in the F group at week 16 (P,0·05). Iron pyrophosphate-fortified fruit juice improves
24 Fe status and may be used to prevent Fe-deficiency anaemia.
25 Key words: Fortification: Ferric pyrophosphate: Iron-deficiency anaemia: Iron status: Women
26 Nutritional Fe deficiency has been identified as one of
27 the ten leading factors for disease, disability and death
28 in the world today. An estimated two billion people are
29 affected, and the population at risk includes women
30 of child-bearing age and children. It is the only highly
31 frequent nutritional deficiency in developing and deve-
32 loped countries(1).
33 Dietary strategies for combating Fe deficiency include Fe
34 supplementation, dietary modification and diversification,
35 and food fortification(2). Our research group has recently
36 observed in young women that the current RDA of 18 mg
37 Fe/d(3,4) was not easily reached, even though the volun-
38 teers consumed five portions of red meat and two portions
39 of poultry per week(5). Supplementation with doses of Fe
40$100 mg/d is efficacious to increase Fe status, but its
41major limitation is low compliance due to gastrointestinal
42discomfort(2). Finally, fortification is widely considered
43to be the most practical and cost-effective prevention pro-
44gramme(6). However, Fe is the most challenging micro-
45nutrient to add to foods, because the Fe compounds that
46have the best bioavailability tend to be those that interact
47most strongly with food constituents producing undesir-
48able organoleptic changes(7). Among Fe fortificants, ferric
49pyrophosphate allows appropriate food processing, and
50it is easily and effectively absorbed while producing neg-
51ligible colour and palatability changes(8–10).
52It is well known that the food matrix strongly affects
53Fe bioavailability(11). Therefore, in addition to the Fe salt,
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54 the effectiveness of consuming Fe fortificants is highly
55 dependent on the type of food used.
56 Ascorbic acid (AA) is the most important enhancer of Fe
57 absorption, both for its ability to improve Fe absorption
58 in the lumen and for overcoming the negative effect of
59 inhibitors(12–14). However, there are doubts concerning
60 the applicability of single-meal results to the practical diet.
61 Cook & Reddy(15) studied Fe absorption from three diets
62 varying in AA and concluded that the effect of vitamin C
63 on Fe absorption from a complete diet was far less pro-
64 nounced than that from single meals. A better Fe status
65 is reached when AA is consumed with meals containing
66 substantial amounts of added Fe(10,13).
67 Nevertheless, studies that used foods with a naturally
68 high content of AA are scarce(16). Fruit juices can contain
69 high quantities of vitamin C, low pH and no Fe absorption
70 inhibitors, and should be considered as target products to
71 fortify with Fe.
72 An orange juice fortified with iron sulphate (2 mg Fe/
73 100 ml) given to Brazilian preschool children during
74 4 months (mean Fe intake 5·7 mg/d) increased Hb levels
75 and decreased the percentage of anaemic children from
76 60 to 20 %(16). Other studies have been performed using
77 multiple-micronutrient-fortified powdered beverages con-
78 taining iron bis-glycinate. These beverages reduced the
79 overall prevalence of anaemia in children, adolescent
80 girls and pregnant women of developing countries(17–21).
81 The present study therefore aims to investigate the
82 influence of the consumption, as a part of the usual diet,
83 of an Fe-fortified fruit juice on Fe metabolism in young
84 Spanish Fe-deficient women.
85 This trial was registered at clinicaltrials.gov as
86 NCT01135576.
87 Subjects and methods
88 The present study was designed and carried out following
89 the statement guidelines of the Consolidated Standards
90 of Reporting Trials(22).
91 Subjects
92 Volunteers were recruited by different announcements
93 in press, university campus and web pages of Madrid.
94 The study was also verbally promoted at public events.
95 The principal variable for the calculation of sample size
96 was ferritin, with a mean value for the deficient population
97 of 11 (SD 5) ng/ml. It was calculated that a minimum of
98 sixty-three subjects with low Fe stores would be required
99 in each group to demonstrate a difference of 2·5 units in
100 serum ferritin between two treatments at 80 % power and
101 confidence level at 95 %.
102 Women aged 18–35 years, non-smoker, non-pregnant,
103 non-breast-feeding, with low Fe stores, defined as serum
104 ferritin ,40 ng/ml and Hb $110 g/l, were included inQ2
105 the present study. The cut-off value for serum ferritin
106was selected because a normal or elevated ferritin
107value does not exclude the presence of Fe deficiency,
108and cut-off ranges between 25 and 50 ng/ml are usually
109considered in studies dealing with predisposition to
110anaemia(5,23). Subjects were excluded from the study if
111they had amenorrhoea, menopause or any known health
112problems likely to influence Fe status including Fe
113metabolism-related diseases (Fe deficiency anaemia,
114thalassaemia and haemochromatosis), chronic gastric dis-
115eases (inflammatory bowel disease, Crohn’s disease, gastric
116ulcers, celiac disease and haemorrhagic diseases), renal
117disease or allergy to any of the components of the assay
118juices. Other exclusion criteria were blood donors or to
119have regularly consumed Fe or AA supplements within
120the 4 months before participating in the intervention.
121A group of 259 women contacted the research group in
122order to participate in the study, but only 163 underwent
123screening. Out of the 163 women, thirty-three were
124excluded (twenty-eight did not meet the inclusion criteria
125and five refused to participate). Finally, a total of 130
126women agreed to participate in the nutritional intervention.
127They were randomised into two groups: fortified (F) and
128placebo (P). All volunteers of the F group completed the
129assay while eight participants of the P group abandoned
130the intervention (Fig. 1).
131Participating women were instructed not to deviate from
132their regular habits and to maintain their normal diet and
133exercise level during the 4 months.
134The present study was conducted according to the
135guidelines laid down in the Declaration of Helsinki, and
136all procedures involving human subjects/patients were
137approved by the Clinical Research Ethics Committee of
138Hospital Puerta de Hierro, Madrid. Written informed
139consent was obtained from all subjects.
140Study design
141The study consisted of a randomised double-blind study
142controlled by placebo of 16 weeks of duration.
143The volunteers recruited were randomly allocated into
144two groups, using the RAND function in Excel (Microsoft
145Office 2003). One group consumed, as a supplement to
146their usual diet, 500 ml/d of the Fe-fortified fruit juice
147(F group, n 64), whereas the other consumed 500 ml/d
148of the placebo fruit juice (P group, n 66). Fortified and
149placebo juices were manufactured in 500 ml cartons
150and in two different tastes (orange and peach apple) to
151achieve compliance. The fortified juice supplied 18 mg
152Fe/500 ml carton, in the form of microencapsulated iron
153pyrophosphate coated with lecithin, equivalent to 100 %
154of the RDA/d(3,4). All juices were fortified with vitamin
155C. Nutritional composition of the juices was facilitated by
156the manufacturer (Grupo Leche Pascual, Burgos, Spain).
157Orange juices provided (per 100 ml) 188 kJ, 0·6 g of pro-
158tein, 10·5 g of carbohydrate and 19 mg of vitamin C; the
159Fe-fortified orange juice provided 3·6 mg of Fe, whereas
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160 the placebo juice had 0·084 mg. Peach apple juices
161 provided (per 100 ml) 201 kJ, 0·6 g of protein, 11·3 g of
162 carbohydrate and 19 mg of vitamin C; the Fe-fortified
163 peach apple juice provided 3·6 mg of Fe, whereas the
164 placebo juice had 0·136 mg.
165 Participants were instructed to alternate between juice
166 flavours (orange juice one day, peach apple juice the
167 next day). The 500 ml carton had to be drunk all at once
168 separately from meals (by at least 2 h) and shaken before
169 consumption. Volunteers who could not drink the juice
170 one day were instructed to consume two juice cartons
171 the following day.
172 Dietary control and compliance
173 Each subject’s dietary intake was evaluated at baseline and
174 monthly to control any possible changes in energy and
175 nutrient intakes. They completed a 72 h detailed dietary
176 intake report, previously validated and proved valuable
177 to assess nutrient intake(24,25), specifying the types of
178 food consumed and serving weights. Daily food, energy
179 intake, nutrient intake and energy provided by macronutri-
180 ents were calculated by an computer application using the
181Spanish Food Composition Database(26). The compliance
182of the study was assessed monthly by questionnaires and
183personal interview when volunteers underwent blood
184sampling.
185Anthropometric, blood pressure and physical activity
186determinations
187Once a month, anthropometric measures were taken using
188standardised procedures. Body weight was measured with
189a calibrated Seca scale (to a precision of 100 g), and height
190was measured at baseline with a stadiometer incorporated
191into the scale. Duplicate waist circumference was taken to
192the nearest 0·1 cm using an inelastic, flexible tape measure.
193BMI was calculated as weight/height squared (kg/m2).
194To avoid inter-examiner variability, one trained member
195of the research team did all anthropometric determinations.
196International manual procedures were used(27).
197Physical activity was assessed by a validated question-
198naire after weeks 4 and 12. This questionnaire was com-
199pleted during face-to-face interviews conducted by a
200trained dietitian. Women were asked about their occu-
201pation, sleeping hours and additional activities at work
Assessed for
eligibility (n 163)
Excluded (n 33)
Not meeting inclusion
criteria (n 28)
Refused to participate
(n 5)
Randomised
(n 130)
Allocated to P group (n 66)
Received allocated
intervention (n 62)
Did not receive allocated
intervention (n 4):
(1) Refused to participate (n 3)
(2) Kidney infection before
     the study (n 1)
Lost to follow-up; give reasons
(n 4)
(1) Knee sprain (n 1)
(2) Discomfort caused by juice (n 1)
(3) Change of residence (n 2)
Analysed (n 58)
Excluded from analysis
(n 0)
Allocated to F group (n 64)
Received allocated
intervention (n 64)
Did not receive allocated
intervention (n 0)
Lost to follow-up
(n 0)
Analysed (n 64)
Excluded from analysis
(n 0)
Contacted with the
research group (n 259)
Fig. 1. Diagram of the Consolidated Standards of Reporting Trials.
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202 and during the rest of the day. The physical activity
203 questionnaire included representative values expressed
204 as multiples of resting energy expenditure. Average
205 daily exercise was calculated taking into account the
206 intensity level and time spent on each activity. Activities
207 were divided into five categories and expressed as an
208 activity factor (resting ¼ 1, very light ¼ 1·5, light ¼ 2·5,
209 moderate ¼ 5 and heavy ¼ 7)(28).
210 In addition, every 4 weeks, women completed a
211 questionnaire about physical discomfort or health pro-
212 blems, medication use and changes in their normal routine.
213 Blood sampling and biochemical assays
214 Volunteers attended the laboratory facilities at baseline,
215 4, 8, 12 and 16 weeks. Blood samples were collected
216 by venepuncture after a 12 h fasting period. Serum and
217 plasma were obtained after centrifugation at 1000 g for
218 15 min and stored at 2808C.
219 Total erythrocytes, haematocrit, mean corpuscular
220 volume, red blood cell distribution width (RDW) and Hb
221 were determined following standard laboratory techniques
222 using the Symex NE 9100 automated haematology analyser
223 (Symex, Kobe, Japan). Serum Fe, serum ferritin and serum
224 transferrin were determined by the Modular Analytics
225 Serum Work Area analyser (Roche, Basel, Switzerland).
226 Total iron-binding capacity (TIBC) and transferrin satu-
227 ration were calculated as follows:
TIBC ðmmol=lÞ ¼ 25·1 £ transferrin ðg=lÞ;
Transferrin saturation ¼ serum Fe ðmmol=lÞ=TIBC £ 100:
228 Serum soluble transferrin receptor (sTfR) concentration
229 was determined using an ELISA technique (sTfR Human
230 ELISA; Biovendor, Heidelberg, Germany) and erythrocyte
231 zinc protoporphyrin (ZnPP) by haematofluorophotometry
232 (haematofluorophotometer AVIV 206; Izasa, Barcelona,
233 Spain). Values of ZnPP mg/mg Hb were converted to
234 mmol/mol haem of erythrocyte protoporphyrin by using
235 a factor of 25·76 according to the AVIV conversion tables.Q3
236 All determinations were subjected to the ISO 9001-2000
237 requirements, except for the transferrin receptor; the
238 intra-assay CV of this determination was 3·5 % and the
239 inter-assay CV was 4·3 %.
240 Statistical analysis
241 Data are presented as means and standard deviations.
242 A normal distribution of variables was determined by
243 the Kolmogorov–Smirnov test. Serum ferritin values
244 were log-transformed for statistical testing. A two-way
245 repeated-measures ANOVA was applied. Because a signi-
246 ficant group £ time interaction was found for the main
247 variables (ferritin, transferrin and Hb, P#0·001), the
248 repeated-measures ANOVA and the Bonferroni post hoc
249test were used to study the time effect within groups.
250Comparisons were also made between the F group and
251the P group using ANOVA. A P value of ,0·05 was
252considered significant. Data were analysed using the SPSS
253statistical package for Windows (version 17.0).
254Results
255A total of 122 volunteers completed the study (Fig. 1). Ages
256of the volunteers were 24·5 (SD 5·1) and 24·2 (SD 4·6) years
257for the P and F groups, respectively. Energy and nutrient
258intakes at baseline and week 16 are shown in Table 1.
259No significant differences between groups were found in
260the baseline characteristics of subjects (Tables 2 and 3).
261Compliance rate was confirmed to be very high (approxi-
262mately 100 %).
263Although energy intake did not show significant differ-
264ences between baseline and week 16 in both groups,
265an increase between week 4 and baseline was observed
266to be significant in the F group (9767 v. 8807 kJ/d for
267week 4 and baseline, respectively, P,0·05). A significant
268decrease in the energy percentage from proteins and an
269increase in that from carbohydrates were observed
270during the study in both groups, and a decrease in the
271energy percentage from lipids was observed only in the
272F group. The differences between the groups were not
273significant (Table 1).
274At baseline, Fe intake was slightly lower in the F group
275compared with the P group, and due to the Fe-fortified
276juice consumption, it was about twice that of the P group
277for the duration of the intervention. In contrast, Fe intake
278of the P group decreased with time, and it was significantly
279lower at week 16 compared with baseline. Vitamin C
Table 1. Energy and macronutrient intakes of iron-deficient women
consuming placebo and iron-fortified fruit juices during 16 weeks
(Mean values and standard deviations)
Baseline Week 16
Groups Mean SD Mean SD Time effect (P)†
Energy (kJ)
Placebo 9452 2179 9826 2493 NS
Fortified 8807 2108 9285 2292 NS
Protein (% energy)
Placebo 15·2 3·9 13·0 2·4 ,0·001
Fortified 14·6 2·4 13·6 2·3 0·004
Carbohydrate (% energy)
Placebo 41·2 7·3 45·0 7·3 0·001
Fortified 41·2 6·2 44·6 6·6 ,0·001
Lipid (% energy)
Placebo 39·9 7·8 37·3 6·3 NS
Fortified 39·7 6·5 36·4 6·8 0·001
Fe (mg)
Placebo 15·1 4·7 12·9 4·7 0·001
Fortified 13·7* 5·9 30·4*** 7·5 ,0·001
Vitamin C (mg)
Placebo 145·9 60·1 199·8 64·9 ,0·001
Fortified 118·3 59·3 190·2 66·0 ,0·001
Mean values were significantly different from the placebo group at each point
(measured using one-sided tests): *P,0·05, ***P,0·001.Q4
† Time-point differences were analysed by repeated-measures ANOVA.
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280 intake increased in both groups from baseline, due to juice
281 composition, without significant differences between the
282 P and F groups (Table 1).
283 The intervention induced increases in body weight and
284 BMI, within normal limits (Table 2). Waist circumference
285 did not change during the intervention. Physical activity
286 was unchanged during the study and did not show differ-
287 ences between the groups; it was classified between very
288 light and light (activity factor, 1·68 v. 1·68 in the P and F
289 groups).
290 Table 3 shows the results of haematological and bio-
291 chemical markers. Increases in the values of total erythro-
292 cytes, haematocrit, mean corpuscular volume, RDW, Hb,
293 serum Fe, serum ferritin and transferrin saturation show
294 recovery from Fe deficiency, while increases in serum
295 transferrin, sTfR-2 and ZnPP denote deterioration, as
296 detailed below.
297 Total erythrocytes did not show significant differences
298 between the groups. However, the F group showed signifi-
299 cantly higher values at week 12 compared with week 4.
300 Similarly, haematocrit values were significantly higher at
301 week 12 compared with week 4 in this group, and
302 higher haematocrit levels were shown at weeks 12 and
303 16 in the F group than in the P group (P¼0·01). Mean
304 corpuscular volume decreased slightly at week 12 in the
305 P group, while it tended to increase in the F group; thus,
306 differences between the groups were significant at week 12
307 (P¼0·03). RDW was higher in the F group than in the
308 P group at weeks 4 and 8 (P,0·01 and 0·05, respectively).
309 Hb concentrations did not vary in the P group during the
310 assay (Table 3), but they increased in the F group and were
311 significantly higher at week 8 compared with baseline, and
312 at week 12 compared with the P group (P , 0·05). ZnPP
313 increased in the P group and decreased in the F group
314 during the assay, and the differences between the groups
315 were significant at weeks 8 and 16 (P , 0·05).
316 No changes in serum Fe concentrations were observed
317 due to either group or time (Table 3). Ferritin con-
318 centrations, the principal variable of the present study,
319significantly increased from week 4 in the F group, and
320the values became about 80 % higher compared with the
321P group at the end of the assay. In contrast, no changes
322were observed in the P group. Serum transferrin fluctuated
323above 3000 mg/l in the P group, while in the F group, itQ2
324markedly decreased from week 4 to the end of the assay,
325and the differences between the groups were significant
326(P,0·01). Accordingly, transferrin saturation was signifi-
327cantly higher from week 8 in the F group with respect to
328the P group (P,0·05).
329sTfR concentrations significantly decreased in the F
330group compared with baseline and the P group (signifi-
331cantly at week 16).
332Discussion
333The present study clearly shows that it is feasible to increase
334Fe status in an at-risk population by daily consumption
335of a microencapsulated iron pyrophosphate-fortified fruit
336juice and that the effects are detected in a short period of
337time (4 weeks). This consumption was compatible with
338the usual diet, and the extra daily 18 mg of Fe provided
339in each 500 ml juice carton was 100 % of the RDA(3,4).
340This quantity of Fe is within the range of supplemental
341minerals added in European commercial foods (20 % of
342the RDA/100 ml).
343The study fruit juice was fortified with micronised
344encapsulated iron pyrophosphate coated with lecithin.
345This form of Fe is dispersible in aqueous solution
346and has been demonstrated to be highly bioavailable. Its
347bioavailability is superior to that of non-micronised iron
348pyrophosphate, which has higher particle size, and to
349that of non-encapsulated iron pyrophosphate(9–11,29).
350Roe et al.(30) enriched micronised iron pyrophosphate
351and ferrous sulphate with different Fe stable isotopes,
352and included each Fe form in apple juices to conduct
353an absorption experiment using the technique of the incor-
354poration of Fe isotopes to erythrocytes. They concluded
355that the bioavailability of micronised iron pyrophosphate
356was higher relative to ferrous sulphate, indicating that it
357could be a useful fortifier for liquid food products.
358Several studies using fortified food that supplied amounts
359of Fe similar to the present study have been reported,
360generally showing lower efficacy. The consumption of a
361wheat biscuit enriched with 10 mg of Fe (as encapsulated
362sulphate) during 22 weeks increased iron ferritin but not
363Hb levels in young women(31). A recent study in female
364soldiers who received 56 mg of Fe/d in the form of food
365bars compared with placebo during 9 weeks has shown
366no changes in serum ferritin, transferrin saturation,
367% RDW and sTfR(32). The difference between these two
368studies and ours could be explained by the presence
369of phytates and the absence of AA in their Fe-fortified
370products, while the fruit juices of the present study con-
371tained no phytate and were fortified with AA. When AA
372is present, as in one study giving 16 mg of Fe-fortified
Table 2. Anthropometric values of iron-deficient women consuming
placebo and iron-fortified fruit juices during 16 weeks
(Mean values and standard deviations)
Baseline Week 16
Groups Mean SD Mean SD Time effect (P)*
Weight (kg)
Placebo 57·5 6·4 58·5 6·6 ,0·0001
Fortified 59·6 7·6 60·5 7·8 ,0·0001
BMI (kg/m2)
Placebo 21·6 2·2 22·0 2·2 ,0·0001
Fortified 21·8 2·3 22·1 2·4 ,0·0001
Waist circumference (cm)
Placebo 68·7 4·7 68·8 4·6 NS
Fortified 69·6 5·4 69·8 5·4 NS
Mean values were not significant between the placebo and fortified groups at each
point.Q4
* Time-point differences were analysed by repeated-measures ANOVA.
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373 breakfast cereal with kiwifruit, increases in ferritin and
374 Hb were observed(33), in agreement with the present study.
375 In the present study, the food matrix used was an
376 acidic drink that contained AA with a molar AA:Fe ratio
377 of 1·7:1. Several reports have discussed the importance of
378 this ratio; however, there is no agreement on the optimal
379 ratio to facilitate Fe absorption. A linear relationship
380 between molar AA:Fe ratio and Fe absorption has been
381 suggested(34), but Cook & Reddy(15) did not observe diffe-
382 rences in Fe absorption between diets with AA:Fe ratios
383 of 1·2:1, 2·4:1 and 4·5:1. This was attributed to the fact
384 that Fe absorption was measured from a complete diet
385 and not from individual meals. However, their study was
386 criticised by Hunt(35) because subjects were instructed to
387 select or avoid foods according to their AA content,
388 which resulted in highly variable estimates of reported
389 AA intakes. Shah et al.(36) compared Fe absorption in
390 children consuming meals that were accompanied by
391 either apple or orange juice, to which 5 mg of aqueous
392 ferrous sulphate enriched with a stable isotope was
393 added. They found that Fe absorption was similar to the
394 orange and apple juices, even though the orange juice
395 had much higher vitamin C content.
396The effect of the AA:Fe ratio on Fe bioavailability
397depends on inhibitors present in the food(34), and several
398authors have suggested a ratio of 2:1 for low-phytate con-
399tent foods(34,37), which is equivalent to the ratio of the
400juices assayed in the present study.
401It is also important to consider that volunteers in the pre-
402sent study drank the 500 ml of juice separately at least 2 h
403after the meals; thus, the provided Fe could not interact
404with inhibitors present in the diet. Moreover, the low Fe
405status of these women at the beginning of the assay consti-
406tuted a factor to favour Fe absorption(13). Therefore, the Fe
407supplement given in the form of fruit juices was highly
408bioavailable and was efficacious to improve Fe status in
409Fe-deficient young women.
410The short-term response observed in the present study
411was unexpected, and the effect was clearly shown in the
412principal variable, ferritin, a marker of Fe stores. To our
413knowledge, this is the first study that demonstrates a
414significant increase in this parameter after the consumption
415of an Fe-fortified functional beverage during 1 month.
416Therefore, it was found that in a very short period of
417time, and using a relatively low additional intake of Fe,
Table 3. Haematological and biochemical markers of iron-deficient women consuming placebo and iron-fortified fruit juices during 16 weeks
(Mean values and standard deviations)
Baseline Week 4 Week 8 Week 12 Week 16
Groups Mean SD Mean SD Mean SD Mean SD Mean SD Time effect (P)
Total erythrocytes (£10212/l)
Placebo 4·50 0·35 4·49 0·33 4·48 0·29 4·51 0·34 4·45 0·30 NS
Fortified 4·51a,b 0·30 4·49a 0·32 4·53a,b 0·32 4·56b 0·31 4·53a,b 0·30 0·046
Haematocrit (%)
Placebo 39·3 2·9 39·2 2·8 38·9 2·5 38·9 2·6 38·7 2·6 NS
Fortified 39·0a 2·8 39·4a 2·5 39·4a 2·7 40·1b** 2·6 39·9a,b** 2·4 0·006
Mean corpuscular volume (fl)
Placebo 87·4a 4·8 87·3a 4·3 87·0a,b 4·3 86·5b 4·1 87·0a,b 4·2 0·011
Fortified 86·6a 5·1 87·9b,c 3·9 87·1a,b 4·2 88·1c* 3·6 88·1c 4·0 0·001
Red blood cell distribution width (%)
Placebo 12·7a 0·8 12·8a 0·9 12·9a 0·9 12·9a 0·9 12·8a 0·8 NS
Fortified 13·0a 1·2 13·7b** 2·3 13·5b* 1·9 13·0a 1·2 12·7a 0·7 0·003
Hb (g/l)
Placebo 133 9 133 9 132 8 132 8 132 8 NS
Fortified 132a 9 133a 8 135b 9 136b* 9 136b** 8 ,0·0001
Zinc protoporphyrin (mmol/mol haem)
Placebo – 79·3a,b 26·9 79·9a,b 29·4 76·1a 32·5 86·1b 33·7 0·049
Fortified – 76·5a 28·6 69·7b,c* 26·1 67·1b 24·1 74·6a,c* 19·3 ,0·0001
Serum Fe (mmol/l)
Placebo 14·0 7·1 16·4 10·0 14·4 7·8 15·0 6·9 14·2 6·5 NS
Fortified 15·5 6·5 14·7 7·2 15·2 6·7 15·5 5·8 16·0 8·3 NS
Serum ferritin (ng/ml)
Placebo 26·9 17·9 25·0 17·4 24·8 17·7 23·1 16·2 22·8 14·9 NS
Fortified 25·4a 16·5 30·7b* 13·6 34·1b,c** 14·8 37·3c,d*** 16·5 40·7d*** 17·7 ,0·0001
Serum transferrin (mg/l)Q2
Placebo 3213a 676 3114b 628 3208a,b 618 3104a,b 638 3232a,b 718 0·001
Fortified 3102a 519 2799b** 449 2875b,c*** 486 2806b** 438 2929c** 509 ,0·0001
Transferrin saturation (%)
Placebo 19·2 7·9 19·6 10·3 17·8 9·7 19·1 9·0 17·8 11·7 NS
Fortified 19·7 10·7 23·7 15·3 22·2* 10·8 23·4* 9·9 23·0* 11·3 NS
Soluble transferrin receptor (mg/l)
Placebo 1·41 0·37 – 1·40 0·35 – 1·45 0·53 NS
Fortified 1·48a 0·60 – 1·33b 0·46 – 1·28b* 0·43 0·001
Mean values within the same row with unlike superscript letters were significantly different between the placebo and fortified groups at each point, measured using one-sidedQ4
tests (repeated-measures ANOVA followed by the Bonferroni test): *P,0·05, **P#0·01, ***P#0·001.
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418 the biomarkers of Fe status improved in non-anaemic
419 Fe-deficient women.
420 Moreover, it was observed that markers such as Hb or
421 haematocrit, which were within normal ranges, increased
422 after 3 months. The observed increase in RDW in the
423 enriched group could also indicate a recovery from Fe
424 deficiency. The RDW levels of the F group became
425 higher in the first months, indicating greater variation in
426 width, and returned to baseline levels at the end of the
427 assay, which corresponds to the average lifespan of eryth-
428 rocytes(38). These results are consistent with the observed
429 increase in mean corpuscular volume and haematocrit
430 after the consumption of the Fe-enriched fruit juice.
431 Other indices, sTfR-2 and ZnPP, which are not widely
432 available as standardised clinical determinations, also indi-
433 cate an improvement of Fe status. Both reflect marrow Fe
434 status for erythropoiesis and recovery from Fe deficiency(39).
435 The present study was performed in a European popu-
436 lation at risk of Fe-deficiency anaemia (i.e. young menstruat-
437 ing women with low Fe stores), and it is important to indicate
438 that intake of the juice portions was compatible with the
439 usual diet, and that the amount of Fe ingested daily via
440 the enriched juice was one-fifth of the usual therapeutic
441 dose (100 mg) of Fe. Under these experimental conditions,
442 ferritin levels increased by 80 %. It should be pointed out
443 that once the assay started, none of the volunteers receiving
444 the Fe-fortified juice dropped out and that they did
445 not complain about digestive discomfort. Therefore, these
446 results are outstanding and suggest that Fe-fortified juices
447 could be used as part of the dietary treatment of anaemic
448 patients in order to correct anaemia more effectively.
449 The slight increments of energy intake and body
450 weight indicate high compliance, as all juices contained
451 10 g/100 ml of carbohydrates (non-added sugars). How-
452 ever, mean body-weight gain was only 1 kg, and BMI
453 remained within normal limits during the whole interven-
454 tion. This is a controversial issue because high consump-
455 tion of fruit juices should be limited in order to prevent
456 obesity, especially in children and young people. How-
457 ever, present results show that the percentage of energy
458 from protein and fat is reduced by the inclusion of the
459 daily juices in the diet, and the energy profile tended
460 to be more balanced. In this respect, dietary guidelines
461 recommend 45–60 % of energy from carbohydrates, and
462 concerning sugar intake, even added sugar, the European
463 Food Safety Authority has recently indicated that there
464 were insufficient data to set an upper limit(40). Moreover,
465 Western populations show a low consumption of fruits
466 and vegetables(41,42), and the beneficial effects of these
467 fruit juices on other aspects of health should be explored.
468 Nevertheless, sugar content could be reduced in future
469 products that might be used as alternatives in subjects
470 predisposed to anaemia and also obesity or diabetes.
471 A physiological adaptation appears to occur, since the
472 increase in body weight was observed at the beginning
473 of the assay (data not shown); thus, it is possible that
474energy from foods other than the juice decreased to
475compensate for the energy provided by the juices. It should
476be pointed out that none of the Fe-deficient women parti-
477cipating in this intervention were obese, and that their
478physical activity was unchanged during the study.
479Fe-fortified juice consumption should be recommended to
480individuals with predisposition to Fe-deficiency anaemia but
481not to those at risk of excessive Fe intake who do not need to
482increase their Fe supply, such as patients with Fe overload(43).
483Therefore, consumption of an Fe-fortified fruit juice may be
484considered as a supplement to prevent Fe-deficient anaemia
485in population risk groups, such as women of child-bearing
486age, pregnant women or children. These groups have a
487high acceptance of fruit juices, and the concept of functional
488foods also has high acceptance in developed countries.
489The present study can have repercussions on public health
490as prevention of one of the most widespread diseases will
491have important economic impact, decreasing the need to
492use public health services and pharmaceutical Fe sup-
493plements. The cost benefits of the consumption of this
494Fe-fortified food compared with those of the pharmaceutical
495therapy and health care services should be studied. In
496fact, in the present study, consumption of the Fe-fortified
497juice led to a recovery from depleted Fe stores (ferritin
498,12ng/ml), with only one woman remaining depleted.
499Further studies should be focused on the effectiveness of
500this Fe-fortified beverage in subjects according to their
501genetic background, in the line of previous studies(43,44).
502Consumer aspects such as the optimal amount of fruit
503juice to be drunk, according to concentration of the Fe
504salt to be included, cost, palatable aspects and acceptability
505should also be investigated. Finally, the effect of such
506Fe-enriched juices on subjects with Fe-deficiency anaemia,
507obesity, diabetes or CVD and their corresponding nutri-
508genomic aspects should also be studied.
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